Goldman Sachs downgraded Icon (ICLR) to Neutral from Buy with a price target of $200, down from $250. While the firm continues to believe that the company is one of the leaders in the clinical Contract Research Organization space, it is now less positive on the near term outlook for Icon as a pure play CRO following less consistent performance in recent quarters, combined with a weaker than expected demand environment, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICLR:
Questions or Comments about the article? Write to editor@tipranks.com